Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tedizolid PK in Infants and Neonates
NCT03217565Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2019
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of tedizolid in Gram-positive bacterial infection, sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Drug Concentration, Area Under the Concentration-time Curve From Time 0 to Infinity and 3 more. Started Feb 2019; status: completed.
02
Drugs
tedizolid
03
Conditions
Gram-positive bacterial infection
Beyond the preview
Go deeper on NCT03217565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03217565.